Arecor, Sequel partner to advance diabetes treatment through clinical trials and beyond 

CAMBRIDGE, U.K. - Arecor Therapeutics, a biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, has signed a co-development agreement with Sequel Med Tech, a company that is developing insulin delivery technologies. Part of the agreement: 

• Combining Arecor’s AT278 (500U/ml) with Sequel’s twiist automated insulin deliver (AID) system powered by Tidepool; and 
• Implementing a royalty financing agreement with Ligand Pharmaceuticals to raise non-dilutive capital of up to $11 million. 

“The co-development agreement for AT278 and the non-dilutive fund raising via the monetization agreement are both major strategic achievements for Arecor,” said Sarah Howel, CEO of Arecor. “The Sequel agreement marks a key milestone, furthering our ambitions to realize AT278’s significant benefits for people living with diabetes, as well as building substantial value for our shareholders. The funding realized through the monetization of specific royalty rights enables us to accelerate AT278’s clinical development and extends our cash runway to 1H 2027 without diluting our shareholders.” 

Under the terms, Arecor and Sequel will co-fund all trial-enabling development activities for the AT278-AID System development program to achieve Phase 2 trial-ready status. Each company will commit up to $1.3 million to accelerate and fund all Phase 2 clinical trial-enabling development work. This will include regulatory interactions and filings with the U.S. Food and Drug Administration (FDA), clinical trial batch manufacturing and AID System compatibility work. Work will commence immediately and is expected to be completed during the first half of 2026, culminating in the filing of an IND (Investigational New Drug). If approved, the program would be ready to enter a pivotal Phase 2 clinical study during 2H 2026. 

Longer term, both companies have confirmed their strategic intent to enter a broader, co-development and commercialization partnership. This would enable the further development and future commercialization of AT278 in a next generation AID system, serving a key unmet patient need in a high value market.